Welcome to our dedicated page for LeMaitre Vascular news (Ticker: LMAT), a resource for investors and traders seeking the latest updates and insights on LeMaitre Vascular stock.
LeMaitre Vascular, Inc. (Nasdaq: LMAT) is a leading provider of medical devices and implants for the treatment of peripheral vascular disease, a condition that affects over 200 million people globally. The company develops, manufactures, and markets disposable and implantable vascular devices aimed at addressing the needs of vascular surgeons. LeMaitre Vascular offers a diversified product portfolio that includes angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems.
Headquartered in Burlington, Massachusetts, LeMaitre's products are utilized during open vascular surgeries, primarily focusing on several anatomical areas such as the carotid, lower extremities, upper extremities, and aorta. The company's lower extremities product line generates the highest revenue, followed by the carotid product line. In recent financial updates, the company reported significant growth in sales across various product categories including bovine patches, valvulotomes, and carotid shunts.
LeMaitre Vascular continues to demonstrate robust financial health. For Q3 2023, the company reported a 21% increase in sales and a 49% rise in operating income, driven by price increases and operational efficiencies. Operating income for Q4 2023 was up 46%, reflecting strong sales growth and improved gross margins. In addition, LeMaitre has a share repurchase program and regularly pays dividends to its shareholders, exemplifying its commitment to shareholder value.
Furthermore, LeMaitre Vascular is focused on expanding its global footprint. Sales in the Americas, EMEA, and APAC regions have shown substantial growth, contributing significantly to the company's revenue. The company also emphasizes compliance with global regulatory requirements, ensuring that its products meet stringent quality standards.
LeMaitre frequently engages with investors through earnings calls, providing transparency about its financial performance and strategic outlook. The company remains committed to innovation and development, constantly working on new projects to enhance its product offerings and address emerging market needs.
For more information about LeMaitre Vascular and its latest updates, visit their official website at www.lemaitre.com.
LeMaitre Vascular (Nasdaq: LMAT) has announced the pricing of $150 million in 2.50% Convertible Senior Notes due 2030. The notes will be sold to qualified institutional buyers with settlement scheduled for December 19, 2024. The company granted initial purchasers an option to buy an additional $22.5 million in notes.
The notes will accrue interest at 2.50% annually, payable semi-annually, and mature on February 1, 2030. The initial conversion rate is 8.3521 shares per $1,000 principal amount, representing a conversion price of $119.73 per share - a 30% premium over the current stock price of $92.10. The net proceeds, estimated at $145.9 million (or $167.8 million if additional notes are purchased), will be used for working capital and general purposes, including potential acquisitions.
LeMaitre Vascular (LMAT) announced plans to offer $150 million in Convertible Senior Notes due 2030, with an additional $22.5 million option for initial purchasers. The notes will be senior, unsecured obligations with semi-annual interest payments, convertible into cash, LMAT common stock, or a combination at LeMaitre's discretion.
The notes will be redeemable after February 5, 2028, if LMAT's stock price exceeds 130% of the conversion price. Noteholders can require LeMaitre to repurchase notes if fundamental changes occur. The company plans to use proceeds for working capital and general purposes, including potential acquisitions. The offering is to qualified institutional buyers under Rule 144A.
LeMaitre Vascular (Nasdaq:LMAT) has announced its participation in two major investor conferences this December. David Roberts, President, will present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024, at 3:30 PM EST in New York City. Additionally, he will present at the Stifel "MedTech Madness" West Coast Bus Tour on December 12, 2024, at 11:45 AM PST in Menlo Park, California.
LeMaitre Vascular (Nasdaq:LMAT) has announced its participation in three major investor conferences this November. David Roberts, President, will present at the UBS Global Healthcare Conference in Rancho Palos Verdes on November 13 at 7:15 AM PT, Stifel's Healthcare Conference in New York City on November 19 at 1:50 PM ET, and the Wolfe Research Healthcare Conference in New York City on November 20 at 2:00 PM ET.
LeMaitre specializes in devices and implants for peripheral vascular disease treatment, serving over 200 million affected patients worldwide. The company focuses on developing and manufacturing vascular devices for surgeons, offering a diverse portfolio of branded products for arteries and veins outside the heart.
LeMaitre (LMAT) reported strong Q3 2024 results with sales reaching $54.8 million, up 16% year-over-year. The company achieved notable improvements with gross margin increasing to 67.8% (+280 bps) and operating income rising 43% to $13.1 million. Key growth drivers included grafts (+24%), patches (+13%), and carotid shunts (+18%). Regional performance showed APAC sales up 24%, EMEA up 22%, and Americas up 12%. The company announced a $0.16 quarterly dividend and raised its full-year 2024 guidance, projecting sales of $219.0-221.0 million and an operating margin of 24%, up from 19% in 2023.
LeMaitre Vascular (Nasdaq:LMAT) has announced that it will release its third quarter 2024 financial results on Thursday, October 31, 2024, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook.
Interested parties can access the live call by registering online, after which they will receive dial-in information and a PIN. An audio webcast will also be available live and for replay at www.lemaitre.com/investor.
LeMaitre is a provider of devices, implants, and services for the treatment of peripheral vascular disease, a condition affecting over 200 million people worldwide. The company focuses on developing, manufacturing, and marketing disposable and implantable vascular devices for vascular surgeons.
LeMaitre Vascular (Nasdaq: LMAT) has announced its participation in three major investor conferences this September. The company's management will be presenting at:
- The Morgan Stanley 22nd Annual Global Healthcare Conference on September 4, 2024, in New York, with President David Roberts presenting at 5:35 PM EST.
- The Barrington Research Fall Investment Conference (Virtual) on September 12, 2024, where Chairman & CEO George W. LeMaitre will host one-on-one meetings.
- The Cantor Fitzgerald 2024 Global Healthcare Conference on September 19, 2024, in New York, with David Roberts presenting at 8:00 AM EST.
These conferences provide LeMaitre Vascular with opportunities to engage with investors and showcase their business strategies and performance.
LeMaitre (Nasdaq:LMAT) reported strong Q2 2024 financial results, with sales reaching $55.8 million, up 11% (12% organic) year-over-year. The company saw significant growth in key product lines and regions, with allografts up 30%, bovine patches up 12%, and carotid shunts up 22%. Geographically, APAC sales increased 20%, EMEA 13%, and the Americas 10%.
Notably, gross margin improved to 68.9%, a 490 basis point increase from Q2 2023, driven by manufacturing efficiencies and higher average selling prices. Operating income surged 52% to $14.4 million, with net income up 46% to $11.8 million. The company announced a quarterly dividend of $0.16 per share and provided an optimistic outlook for Q3 and full-year 2024, projecting continued sales and profit growth.
LeMaitre Vascular (Nasdaq: LMAT) has announced the release date for its second quarter 2024 financial results. The company will disclose its earnings on Thursday, August 1, 2024, after the market closes. Following the release, LeMaitre has scheduled a conference call at 5:00 PM ET to discuss the results, business highlights, and company outlook.
Interested parties can access the live call by registering online, after which they will receive dial-in information and a PIN. Additionally, an audio webcast will be available live and for replay through the company's investor relations website.
LeMaitre Vascular (Nasdaq: LMAT) announced that its Chairman & CEO, George W. LeMaitre, will present at the 2024 Jefferies Global Healthcare Conference on June 6, 2024, at 11:00 AM ET.
The event will take place at the Marriott Marquis in New York City. LeMaitre specializes in devices, implants, and services for peripheral vascular disease, which affects over 200 million people globally.
The company focuses on developing, manufacturing, and marketing disposable and implantable vascular devices for vascular surgeons.
FAQ
What is the current stock price of LeMaitre Vascular (LMAT)?
What is the market cap of LeMaitre Vascular (LMAT)?
What products does LeMaitre Vascular offer?
Where is LeMaitre Vascular headquartered?
In which medical areas are LeMaitre's products primarily used?
What was the company's financial performance in Q3 2023?
How does LeMaitre Vascular engage with its investors?
What regions contribute significantly to LeMaitre's revenue?
Does LeMaitre Vascular pay dividends to its shareholders?
What recent financial achievements has LeMaitre Vascular reported?
How does LeMaitre ensure the quality of its products?
Where can I find more information about LeMaitre Vascular?
